Real-time enrollment status for this autosomal dominant hypocalcemia type 1 (adh1) clinical trial
Current Status
Recruiting
Checked: July 13, 2026 at 11:39 PM UTC
| NCT Number | NCT07080385 |
| Recruiting Status | Recruiting |
| Condition | Autosomal Dominant Hypocalcemia Type 1 (ADH1) |
| Phase | Clinical Trial |
| Target Enrollment | 28 participants |
| Active Locations | 4 sites in the US |
| Sponsor | Calcilytix Therapeutics, Inc., a BridgeBio company |
| Last Updated on CT.gov | April 22, 2026 (Apr 22, 2026) |
As of July 13, 2026: Clinical trial NCT07080385 is currently recruiting participants. This clinical trial study for autosomal dominant hypocalcemia type 1 (adh1) is actively seeking new participants at 4 locations across the United States. The study is sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07080385 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 4 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07080385 was last updated Apr 22, 2026 (April 22, 2026). HelloStudys verifies this status automatically.